Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.jhep.2009.10.008
DC FieldValue
dc.titleAZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
dc.contributor.authorHuynh, H
dc.contributor.authorNgo, V.C.
dc.contributor.authorSoo, K.C.
dc.contributor.authorKoong, H.N.
dc.contributor.authorPoon, D.
dc.contributor.authorChoo, S.P.
dc.contributor.authorToh, H.C.
dc.contributor.authorThng, C.H.
dc.contributor.authorChow, P.
dc.contributor.authorOng, H.S.
dc.contributor.authorChung, A.
dc.contributor.authorGoh, B.C.
dc.contributor.authorSmith, P.D.
dc.date.accessioned2011-09-29T05:54:20Z
dc.date.available2011-09-29T05:54:20Z
dc.date.issued2010
dc.identifier.citationHuynh, H, Ngo, V.C., Soo, K.C., Koong, H.N., Poon, D., Choo, S.P., Toh, H.C., Thng, C.H., Chow, P., Ong, H.S., Chung, A., Goh, B.C., Smith, P.D. (2010). AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). Journal of Hepatology 52 (1) : 79-87. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jhep.2009.10.008
dc.identifier.issn01688278
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/27256
dc.description.abstractBackground & Aims: Hepatocellular carcinoma (HCC) is a particularly vascularized solid tumor where the Raf/MEK/ERK pathway is activated; suggesting that inhibition of this pathway may have therapeutic potential. Methods: We treated patient-derived HCC xenografts with (i) sorafenib, (ii) AZD6244 (ARRY-142886), and (iii) sorafenib plus AZD6244. Western blotting was employed to determine pharmacodynamic changes in biomarkers relevant to both angiogenesis and MEK signaling. Apoptosis, microvessel density, and cell proliferation were analyzed by immunohistochemistry. Results: We report here that sorafenib treatment resulted in suppression of tumor growth, reduction in cell proliferation, induction of apoptosis and inhibition of mTOR targets. Sorafenib-induced elevation of the insulin-like growth factor receptor 1 (IGF-1R), phospho-c-Raf Ser338, phospho-MEK Ser217/221 and phospho-ERK Thr202/Tyr204 was attenuated by co-treating cells with anti-human IGF-1R antibody or over-expression of activated mutant p70S6K. Pharmacological inhibition of the MEK/ERK pathway by AZD6244 enhanced the anti-tumor effect of sorafenib in both orthotopic and ectopic models of HCC. Such inhibition led to a further increase in pro-apoptotic Bim, apoptosis and a profound inhibition of cell proliferation. Conclusion: Our findings underscore the potential of a combined therapeutic approach with sorafenib and MEK inhibitors in the treatment of HCC. © 2009 European Association for the Study of the Liver.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.jhep.2009.10.008
dc.sourceScopus
dc.subjectAngiogenesis
dc.subjectApoptosis
dc.subjectCombined therapy
dc.subjectGrowth inhibition
dc.subjectHCC xenografts
dc.typeArticle
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.1016/j.jhep.2009.10.008
dc.description.sourcetitleJournal of Hepatology
dc.description.volume52
dc.description.issue1
dc.description.page79-87
dc.identifier.isiut000273509600012
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

58
checked on Aug 13, 2019

WEB OF SCIENCETM
Citations

58
checked on Aug 5, 2019

Page view(s)

204
checked on Aug 10, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.